Clinical Trial Update: SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer

View source ↗

Summary

A clinical trial evaluating stereotactic ablative radiotherapy (SABR) combined with targeted therapy and anti-PD-1 therapy for recurrent or metastatic renal cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Snippet

Sponsor: Peking University First Hospital | Conditions: Radiation Therapy, Metastatic Renal Cancer | Status: RECRUITING